Introducing SERB Pharmaceuticals

SERB Pharmaceuticals represents the combination of SERB, BTG Specialty Pharmaceuticals and Veriton Pharma to form a new, growing specialty pharmaceutical company focused on critical care and rare diseases.

We make treating complex and life-threatening conditions possible; supporting clinicians, healthcare systems and governments while offering hope to patients and their families.

Who we are

SERB began in the 1950s as Société d’Études et de Recherches Biologiques (Company for Biologic Study and Research).

Today SERB has the broadest antidote portfolio in the world, including medical countermeasures for chemical, biological, radiological and nuclear (CBRN) risks.

As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain.

Improving patients’ quality of life and offering hope is what motivates and inspires us.




Dedicated employees

Direct sales in






Latest news

  • 11 May 2023
    SERB Pharmaceuticals and SFJ Pharmaceuticals announce a U.S. partnership for bentracimab, a ticagrelor reversal agent
    SERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ Pharmaceuticals.
  • 02 May 2023
    New Publication Compares Total Vials of CroFab® and Anavip® Administered to Treat US Rattlesnake Envenomation
    Analysis shows patients treated with CroFab require fewer total vials of antivenom, and fewer administrations to achieve control, than Anavip.
  • 15 March 2023
    New economic analysis of Voraxaze® (glucarpidase) in patients with delayed methotrexate elimination
    Model simulation shows cost of timely Voraxaze® use is offset by shorter hospital stays and associated with substantially improved clinical outcomes West Conshohocken, PA, 15 March 2023:  BTG Pharmaceuticals, a SERB company, today announces the publication of an economic simulation assessing the value of Voraxaze® (glucarpidase) for treating adult patients in the United States who […]

Latest insight

When Choosing Antivenom, Look at Cost Per Treatment—Not Cost Per Vial

Recent NASBR data suggests that the difference in total treatment cost between antivenom products is probably much less than healthcare providers think.

Read more
You are leaving the global corporate website
This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
Choose your region